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Background: The role of brain metabolites as biological correlates of the intensity, symptoms, 
and course of major depression has not been determined. It has also been inconclusive whether 
the change in brain metabolites, measured with proton magnetic spectroscopy, could be cor-
related with the treatment outcome. 
Methods: Proton magnetic spectroscopy was performed in 29 participants with a first episode 
of moderate depression occurring in the left dorsolateral prefrontal cortex and left amygdala at 
baseline and after 8 weeks of antidepressant treatment with escitalopram. The Montgomery-
Asberg Depression Rating Scale, the Hamilton Rating Scale for Depression, and the Beck 
Depression Inventory were used to assess the intensity of depression at baseline and at the 
endpoint of the study. At endpoint, the participants were identified as responders (n=17) or 
nonresponders (n=12) to the antidepressant therapy. 
Results: There was no significant change in the N-acetyl aspartate/creatine ratio (NAA/Cr) after 
treatment with antidepressant medication. The baseline and endpoint NAA/Cr ratios were not 
significantly different between the responder and nonresponder groups. The correlation between 
NAA/Cr and changes in the scores of clinical scales were not significant in either group. 
Conclusion: This study could not confirm any significant changes in NAA after antidepressant 
treatment in the first episode of moderate depression, or in regard to therapy response in the left 
dorsolateral prefrontal cortex or left amygdala. Further research is necessary to conclude whether 
NAA alterations in the first episode of depression could possibly be different from chronic or 
late-onset depression, and whether NAA alterations in stress-induced (reactive) depression are 
different from endogenous depression. The potential role of NAA as a biomarker of a treatment 
effect has yet to be established. 
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Introduction
The neurobiological findings regarding major depressive disorder (MDD) indicate 
structural, functional, and neurochemical changes in the brain. The most prominent 
results of MDD, in comparison with healthy persons, are changes in brain volume 
in the prefrontal and limbic structures, damage to neurons and glia, and alterations 
in brain metabolism.1 Depression could take various courses, graduating from single 
to numerous episodes, and the symptoms could vary from mild to very severe, with 
different responses to therapy and recovery. Therefore, the significance of determin-
ing the correlation of neurobiological findings in MDD with the clinical symptoms, 
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intensity, treatment response, and course of illness is increas-
ing in many contemporary studies of MDD. 
The prefrontal cortex and limbic structures have been 
suggested to play a key role in the emotional and cognitive 
processing of patients with MDD.2,3 The amygdala is impli-
cated in regulation of emotion, and is strongly connected with 
the prefrontal cortex.4 Studies have found alterations in the 
structure and function of the amygdala in patients with MDD, 
including changes in its volume and an increase in cerebral 
blood flow and glucose metabolism.5,6 The left amygdala 
is considered to be more responsive to emotional stimuli, 
particularly negative stimuli.7 Differences related to depres-
sion have been reported in the left hemispheric white matter 
connections between the frontal and limbic regions.8,9
The dorsolateral prefrontal cortex (DLPFC) is involved 
with integrating sensory and mnemonic information, and 
regulating intellectual function and action.10 Compared 
with healthy persons, there have been alterations in the 
volume and metabolic activity of the DLPFC in patients 
with MDD.11,12
Of particular interest in the frontal cortex and amygdala 
are their interconnections and involvement in mood regula-
tion, supporting the theory of frontolimbic dysregulation in 
depression.13 In post mortem studies, depressive patients 
showed neuronal and glial alterations in these regions, which 
underlie brain metabolite chemistry.14 Neuronal and glial 
alterations are considered to be related to brain metabolite 
changes, such as in N-acetyl aspartate (NAA), choline, 
myo-inositol, and creatine (Cr), and may affect glutamate 
regulation.15 Neurobiological alterations, particularly on 
the left side of the amygdala and DLPFC, are considered to 
be related to the pathophysiology of depression.16
The development of magnetic resonance spectroscopy 
(MRS) has allowed the quantification of brain metabolites 
in real time, as well as follow-up of the changes in brain 
metabolites in different disorders and clinical states. It is 
expected that MRS would provide valid biological markers 
of brain disorders, including mental disorders and biological 
correlates of symptoms and treatment response. Proton mag-
netic resonance spectroscopy (1H-MRS) studies regarding 
MDD have reported different alterations in brain metabo-
lites, such as in NAA, glutamate, gamma-aminobutyric 
acid, choline, and myo-inositol, in different brain regions.17 
Studies using MRS have shown abnormalities in brain 
metabolism in the prefrontal cortex and limbic structures 
in patients with depression.18 So far, MRS studies of the 
amygdala have shown alterations in choline, myo-inositol, 
and glutamate in patients with MDD.19 MRS studies of the 
prefrontal cortex have shown glutamate changes in patients 
with depression.19
NAA is the second most abundant amino acid in the 
human brain. It is localized mostly in neurons, oligoden-
drocyte precursors, and mature oligodendrocytes. NAA 
is considered a neuron-specific metabolite and a marker 
of neuronal viability. Its biological function is not fully 
understood, but it is considered a marker of neuronal loss.20 
Previous MRS studies have found no differences in NAA in 
depressive patients and healthy subjects in the basal ganglia 
and frontal lobes.19,21,22 In contrast, some studies have reported 
a reduction of NAA in different brain regions during late-
onset depression.23–26
Cr is distributed in gray and white matter, and serves as 
a measure of the amount of brain tissue contained within 
an analyzed voxel.27 In the absence of major brain pathol-
ogy, Cr levels are stable over time.16 Many studies have 
confirmed unaltered Cr levels in patients with MDD, and 
Cr levels have been widely used as an internal standard for 
comparison.3,19,28
Antidepressant medication is widely used for the treat-
ment of MDD, as its efficacy has been linked to clinical 
improvement. Still, fewer than 50% of patients with MDD 
show full treatment responses.29 Finding biological markers 
that would predict the response to therapy and outcome of 
treatment would be valuable in clinical practice; much effort 
has been put into achieving this goal.
Many studies report that antidepressants have specific 
effects on brain regions.29 Selective serotonin reuptake 
inhibitors have been found to affect the volumes, activation, 
and biochemistry of brain regions, including the prefrontal 
cortex and amygdala.30–34 It is thought that treatment with 
antidepressant medication could normalize abnormalities in 
corticolimbic function.35,36
Potentially, the findings of neuroimaging may be used 
for monitoring the response to treatment and predicting the 
clinical outcome for MDD patients after treatment.29 Recent 
MRS studies have evaluated the effects of antidepressants on 
brain metabolites in healthy individuals and MDD patients. 
Some studies have reported a significant increase in NAA 
after antidepressant medication or electroconvulsive therapy 
in depressive patients.37–41 However, other studies have found 
no significant changes in brain metabolites after antidepres-
sant treatment in different groups of depressive patients.42–44 
Increases in NAA after antidepressant treatment would mean 
that the treatment had a neurotropic effect, which could 
account for the rise in neuroprotection and in the viability of 
neurons. Based on current knowledge, the correlation between 
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brain metabolite changes and changes in clinical symptoms 
and intensity of MDD during treatment is still not clear. 
The aim of this study was to investigate whether there 
would be any changes in NAA/Cr, measured with 1H-MRS 
in two brain regions, ie, the left DLPFC and left amygdala, 
corresponding to clinical changes in the intensity of MDD in 
depressive patients with regard to therapy response.
Materials and methods
Participants
Twenty-nine patients who had never been treated for men-
tal illness were recruited from an outpatient polyclinic. 
A diagnosis of MDD was made according to the diagnostic 
criteria in the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV).45 A comorbid diagno-
sis, mental or somatic, was the exclusion criterion. Partici-
pants were assigned to take 10 mg/day of escitalopram, an 
antidepressant medication. 1H-MRS was performed before 
starting medication (baseline) and after 8 weeks of therapy 
(endpoint). The Montgomery-Asberg Depression Rating 
Scale (MADRS),46 the Hamilton Rating Scale for Depres-
sion (HAMD, 21-item),47 and the Beck Depression Inventory 
(BDI)48 were used to assess patients at baseline and at week 8 
of antidepressant therapy. At endpoint, participants were 
identified as responders (n=17) or nonresponders (n=12) to 
the antidepressant treatment, based on the change in total 
results according to the scales. Treatment response was 
defined as having a minimum of 50% improvement in the 
total score on the HAMD, MADRS, and BDI from baseline 
to endpoint.49 For the purpose of this study, only patients who 
fulfilled this criterion in all three instruments were defined 
as treatment “responders”. All participants signed informed 
consent forms before participating in the study. The study 
was approved by the institutional ethics committee. 
1h-Mrs analyses
A 1H-MRS examination was performed using a clinical 2.0 T 
system (Gyrex 2T-Prestige, GEMS/Elscint, Haifa, Israel) 
with a quadrate head coil. The subject lay in the supine 
position, with the intersection of the frontal bone and two 
nasal bones (nasion) serving as a landmark. Foam pads were 
used to minimize head motion. Voxels were placed for spec-
troscopy, and all data analyses were performed by a trained 
radiologist who was blind to each subject’s diagnosis. The 
voxels were repositioned in predefined brain areas, which 
were localized in both the left DLPFC and left amygdala. The 
routine imaging studies included a multilane T1-weighted 
spin-echo (650/12/2 [TR/TE/NEX]), a T2-weighted fast spin-
echo (6000/90/2) with an echo train length of 10, and fast 
fluid attenuated inversion recovery (9100/126/1; inversion 
time, 2,200 msec) sequences. Axial T2 fast spin-echo images 
(8500/2200/126) were obtained, followed by placement of 
a single 8 cm3 voxel (15×15×15 mm) over the left DLPFC 
and left amygdala (Figures 1 and 2). 1H-MRS was performed 
Figure 1 left dorsolateral prefrontal cortex. 
Abbreviations: Naa, N-acetyl aspartate; cr, creatine.
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using a point-resolved spectroscopy sequence (1500/54 [TR/
TE]), with 100 averages. Each spectrum was evaluated for 
peak Cr (at 3.03 ppm) and NAA (at 2.02 ppm). The values 
of NAA/Cr ratios were used for the analyses. Analyses of 
the spectral dataset were performed using the software pack-
age program supplied by the manufacturer of the magnetic 
resonance system (Gyrex 2T-Prestige, GEMS/Elscint).
statistical analysis
The statistical analysis was done using Statistica version 10 
software (StatSoft Inc, Tulsa, OK, USA). Data for continu-
ous variables are shown as the mean ± standard deviation, 
while data for categorical variables are laid out as frequen-
cies and/or percentages. Due to the group size, normality 
testing was performed using a Shapiro–Wilk test rather than 
a Kolmogorov–Smirnov test. A between-group analysis 
was done using appropriate parametric or nonparametric 
tests (continuous variables), or chi-square test (categorical 
variables). Correlations between variables measured on an 
interval scale were explored by means of a Pearson or Spear-
man correlation. The statistical significance (type I error 
level) cut-off point was 0.05.
Results
Participants
Of the 29 patients who completed the study, 17 were identi-
fied as responders and 12 as nonresponders at endpoint. There 
were no differences in age, gender, or MADRS baseline 
scores between the responder and nonresponder groups. 
Differences between the groups were significant for baseline 
HAMD and BDI scores, as well as in endpoint scores for all 
three scales (Table 1). 
Mrs results
For all participants, there were no significant differences in 
NAA/Cr ratios between baseline and endpoint MRS in the 
DLPFC (P=0.950) and amygdala (P=0.649; Figure 3). 
After separately analyzing the responder and nonre-
sponder groups, no significant differences were found in 
either region for either group (Figure 4). There were no sig-
nificant differences between the responder and  nonresponder 
groups in the baseline NAA/Cr ratio, with P=0.795 for the 
DLPFC and P=0.718 for the amygdala. Neither the responder 
group nor the nonresponder group showed significant dif-
ferences in endpoint NAA/Cr ratios. For the responder 
group, NAA/Cr in the DLPFC was P=0.805 and P=0.552 in 
the amygdala. For the nonresponder group, NAA/Cr in the 
DLPFC was P=0.862 and P=0.977 in the amygdala.
correlation of change in metabolite 
measures and depression scale scores 
between baseline and endpoint
There was a significant difference in the mean decrease in 
scores on the depression scales between the responder and 
Figure 2 left amygdala. 
Abbreviations: Naa, N-acetyl aspartate; cr, creatine.
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nonresponder groups (Table 2). However, the decrease in 
NAA/Cr ratios in the DLPFC and amygdala was not signifi-
cantly different between the groups. For all three scales, there 
was no significant correlation between the difference in the 
endpoint and baseline scores of the scales, or the difference 
in the endpoint and baseline NAA/Cr ratios, in both regions 
(Table 3) and groups (Table 4). 
Discussion
In this study, no significant change in NAA/Cr, measured 
with 1H-MRS, was found after antidepressant treatment in 
participants experiencing their first episode of moderate 
depression. There was also no difference in the change in 
NAA/Cr between the responder and nonresponder groups. 
These findings suggest there were no effects of antidepressant 
treatment on NAA/Cr that could be observed by 1H-MRS in 
either the frontal or limbic region. 
These results support those of the MRS study reported 
by Kaymak et al in drug-naïve female patients experienc-
ing their first episode of MDD, as no significant metabolic 
alterations to NAA/Cr were found in the left DLPFC after 
8 weeks of antidepressant treatment.43 In our previous 
report, even in a higher magnetic field, we did not observe 
significant changes in NAA/Cr in the left DLPFC after 
6 weeks of antidepressant treatment; the patients were 
diagnosed with comorbid MDD and posttraumatic stress 
disorder, and there was a significant posttreatment increase 
in choline.44 
In contrast with these findings, several MRS studies on 
the medial frontal cortex and the hippocampus found an 
increase in NAA/Cr in depressive patients after antidepres-
sant treatment.37,38,50 Taylor et al found an increase of NAA/Cr 
in the medial frontal cortex after only 7 days of antidepressant 
treatment in depressive patients treated with escitalopram, 
compared with a healthy group given a placebo.9 An increase 
in NAA after treatment would indicate the neurotrophic effect 
of antidepressant medication on the medial frontal cortex and 
the hippocampus. Two studies found a significant increase 
in NAA/Cr in the amygdala and the anterior cingulum after 
electroconvulsive therapy in depressive patients, and reached 
similar conclusions about the neurotrophic effect of antide-
pressant medicine,40,41 while one study did not.42 
Table 1 group characteristics
Participants  
(n=29)
Responders  
(n=17)
Nonresponders  
(n=12)
P-value
age, mean (sD) 46.6±7.5 47.0±5.7 46.0±9.7 0.729*
sex
Male 17 8 9 0.132†
Female 12 9 3
MaDrs baseline, mean ± sD 31.4±5.01 32.3±4.09 0.637*
MaDrs endpoint, mean ± sD 8.9±3.35 23.7±3.85 0.000*
haMD baseline, mean ± sD 25.7±4.09 31.1±4.06 0.002*
haMD endpoint, mean ± sD 8.2±2.94 22.3±2.84 0.000*
BDi baseline, mean ± sD 24.1±8.82 31.1±4.78 0.020*
BDi endpoint, mean ± sD 7.8±3.60 24.9±4.14 0.000*
Naa/cr DlPFc, mean ± sD, baseline 1.30±0.22 1.31±0.20 1.29±0.24 0.795*
Naa/cr amygdala, mean ± sD, baseline 1.23±0.22 1.24±0.21 1.21±0.25 0.718*
Naa/cr DlPFc, mean ± sD, endpoint 1.33±0.20 1.32±0.20 1.34±0.20 0.757*
Naa/cr amygdala, mean ± sD, endpoint 1.21±0.23 1.18±0.23 1.25±0.21 0.471*
Notes: *student’s t-test; †chi-square test. 
Abbreviations: MaDrs, Montgomery-asberg Depression rating scale; haMD, hamilton rating scale for Depression; BDi, Beck Depression inventory; sD, standard 
deviation; Naa/cr, N-acetyl aspartate/creatine ratio; DlPFc, dorsolateral prefrontal cortex.
NAA/Cr F1
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
NAA/Cr F2 NAA/Cr A1 NAA/Cr A2
Figure 3 Box plots of Naa/cr, showing baseline and endpoint in DlPFc and 
amygdala for all subjects. shown are medians (squares), interquartile ranges (boxes), 
and nonoutlier range (whiskers). 
Abbreviations: Naa/cr, N-acetyl aspartate/creatine ratio; DlPFc, dorsolateral 
prefrontal cortex; F1, baseline in DlPFc; F2, endpoint in DlPFc; a1, baseline in 
amygdala; a2, endpoint in amygdala.
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NAA is considered to be a marker of neuronal density. 
Unaltered NAA in MDD could be explained by the absence 
of cellular loss in some groups of depressive patients.19 
According to previous reports, the neuronal cell number in 
patients with MDD is normal.40 Some studies of unmedicated 
MDD patients found no differences in NAA in the left fron-
tal cortex, compared with healthy controls and medicated 
patients.19 Portella et al reported significantly lower NAA 
levels, which were associated with the onset of illness at 
earlier ages, in the ventromedial prefrontal cortex in remitted 
recurrent and chronic patients with MDD.51 Wang et al found 
significantly lower NAA levels in the bilateral DLPFC white 
matter during first-episode treatment of naïve patients with 
MDD, compared with healthy controls.39 In contrast with 
these studies, Milne et al found no significant decrease in 
NAA in either the first-episode or multiple-episode groups.22 
Low NAA levels imply neurodegenerative changes, and 
could be related to age, duration of illness, and number of 
depressive episodes.18,52 In the study by de Diego-Adelino 
et al it was found that metabolic alterations were more 
pronounced in patients with recurrent or chronic depres-
sion.53 Further research is necessary to conclude whether 
NAA alterations in the first episode of depression could be 
different from chronic or late-onset depression, or whether 
stress-induced (reactive) depression could be different from 
endogenous depression. 
There have been high expectations of a correlation 
between biological changes in the brain and the clinical 
Figure 4 Box plots of Naa/cr in responders and nonresponders to antidepressant treatment showing baseline and endpoint in DlPFc and amygdala. shown are medians 
(squares), interquartile ranges (boxes), and nonoutlier range (whiskers). 
Abbreviations: Naa/cr, N-acetyl aspartate/creatine ratio; DlPFc, dorsolateral prefrontal cortex; F1, baseline in DlPFc; F2, endpoint in DlPFc; a1, baseline in amygdala; 
a2, endpoint in amygdala.
NAA/Cr F1
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NAA/Cr F2 NAA/Cr A1 NAA/Cr A2 NAA/Cr F1 NAA/Cr F2 NAA/Cr A1 NAA/Cr A2
Response: no Response: yes
Table 2 changes in scales and Naa/cr ratios from baseline to endpoint
n All subjects Responders Nonresponders P-value
MaDrs 29 -16.75 (8.16) -22.53 (4.62) -8.58 (3.77) 0.001
haMD 29 -13.89 (5.88) -17.53 (4.15) -8.75 (3.69) 0.001
BDi 29 -12.13 (8.30) -16.35 (7.81) -6.17 (4.54) 0.001
Naa/cr a 29 -0.026 (0.260) -0.036 (0.25) -0.003 (0.29) 0.791
Naa/cr F 29 -0.003 (0.241) -0.016 (0.23) 0.016 (0.27) 0.767
Note: Values are shown as the mean (standard deviation). 
Abbreviations: a, amygdala; F, dorsolateral prefrontal cortex; MaDrs, Montgomery-asberg Depression rating scale; haMD, hamilton rating scale for Depression; 
BDi, Beck Depression inventory; Naa/cr, N-acetyl aspartate/creatine ratio.
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changes in the course of MDD, especially with the treatment 
response. In this study, we found no significant differences 
between the responder and nonresponder groups with regard 
to measures of NAA/Cr at baseline and endpoint. Block 
et al found that low baseline NAA and choline levels in 
the hippocampus were associated with a positive treatment 
response, which was considered to be evidence of neuronal 
restoration in the hippocampus.38 Kado et al reported that high 
baseline NAA/Cr levels in the frontal lobes were associated 
with clinical responses in depression in the elderly.52 In addi-
tion, a group of patients with depressive psychosis, who had 
decreased NAA/Cr in their frontal lobes, showed resistance 
to antidepressant medication. Therefore, metabolic reactiv-
ity to antidepressant treatment could be more pronounced in 
patients with low baseline NAA levels as an effect of age, 
duration of MDD, and number of episodes. After electrocon-
vulsive therapy in refractory depressive patients, increased 
NAA levels were observed only in the responder group.41 
In this study, an association could not be established 
between changes in depression intensity and changes in 
metabolites as effects of antidepressant therapy. Neither 
baseline nor after-treatment NAA/Cr levels showed a cor-
relation with the changes in depression intensity observed 
from baseline to the endpoint of the study. As expected, the 
responder group showed significantly more improvement in 
scores on the clinical scales than the nonresponder group. 
Nevertheless, changes measured by the scales were not cor-
related with changes in metabolites, meaning that changes 
in the clinical course and intensity of depression were not 
followed by changes in the level of NAA/Cr, which could 
be measured by MRS. 
Kaymak et al also did not find a correlation between 
NAA and HAMD scores before or after treatment.43 The 
same studies that reported a significant increase in NAA after 
antidepressant treatment did not find a significant correla-
tion between NAA and scores on clinical scales.37,39,50 Block 
et al found a negative correlation between changes measured 
by BDI and changes in NAA after antidepressant treatment 
in their responder group, suggesting the importance of fol-
lowing changes in NAA with regard to treatment response.38 
Sozeri-Varma et al did not find a correlation between metabo-
lite levels and HAMD scores in patients experiencing their 
first episode of mild-to-moderate depression.54
In our group of participants, the severity of depression, 
assessed by scores on the three clinical scales, was moder-
ate, thus excluding the possibility of an overall conclusion 
for patients with more severe depression. Since the severity 
of illness has been associated with the degree of volumetric 
loss in the prefrontal lobes,55 a more pronounced change in 
neuronal viability markers could be better observed in more 
Table 3 correlations of changes in scale scores with changes in Naa/cr ratios from baseline to endpoint
Difference endpoint – baseline
NAA/Cr F NAA/Cr A
Difference endpoint – baseline MaDrs 0.1442 0.0530
P=0.556 P=0.829
haMD -0.0737 0.1338
P=0.764 P=0.585
BDi 0.3044 0.1521
P=0.205 P=0.534
Abbreviations: a, amygdala; F, dorsolateral prefrontal cortex; MaDrs, Montgomery-asberg Depression rating scale; haMD, hamilton rating scale for Depression; 
BDi, Beck Depression inventory; Naa/cr, N-acetyl aspartate/creatine ratio.
Table 4 correlations of changes in scale scores with changes in Naa/cr ratios from baseline to endpoint in responders and 
nonresponders
Responders Nonresponders
Diff NAA/Cr F Diff NAA/Cr A Diff NAA/Cr F Diff NAA/Cr A
Diff MaDrs 0.3563 0.1609 0.0124 -0.6119
P=0.232 P=0.600 P=0.981 P=0.197
Diff haMD -0.1132 0.3163 -0.0579 0.5784
P=0.713 P=0.292 P=0.913 P=0.229
Diff BDi 0.4029 0.1246 0.2950 0.0479
P=0.172 P=0.685 P=0.570 P=0.928
Abbreviations: a, amygdala; F, dorsolateral prefrontal cortex; MaDrs, Montgomery-asberg Depression rating scale; haMD, hamilton rating scale for Depression; 
BDi, Beck Depression inventory; Naa/cr, N-acetyl aspartate/creatine ratio; Diff, difference.
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severely depressed patients. So far, changes in the clinical 
severity of MDD and treatment response have not been 
conclusively correlated with changes in the NAA levels of 
depressed patients. At this point in the research, changes in 
NAA levels, if any, could not be definitely translated to clini-
cal changes during antidepressant treatment. The potential 
role of NAA as a biomarker of treatment effect or improve-
ment of MDD has yet to be established. 
Differences in sample characteristics, acquisition, and 
post-processing parameters could be responsible for the dif-
ferences between this study and other MRS studies. Quantify-
ing and interpreting metabolic information from brain MRS 
is complicated by a number of variables, which can affect 
determination of the apparent concentration.56 There were 
also differences in the selection of participants with regard 
to multiple depressive episodes, therapy resistance, dura-
tion of illness, and comorbidity, as compared with similar 
studies. The sample of depressive participants in this study 
was characterized as first-episode patients who had never 
been treated. However, it is possible that minor depressive 
episodes had occurred previously, and had gone undiagnosed 
and untreated. This sample was comprised of middle-aged 
participants, with no data on previous episodes of depression, 
traumatic events, or insidious organic brain processes, which 
could not be detected at the point of inclusion in the study. 
It would be interesting to study brain metabolites in relation to 
the subsequent course of illness and aging of participants. 
Better selection of MDD patients, which could be done 
with knowledge of the duration of untreated MDD, number 
of episodes, impacts of early stress, and specific depressive 
features, could provide a valid insight into the metabolic 
changes in the brain after antidepressant treatment. In this 
study, after differentiating responders from nonresponders, it 
was observed that the responder group showed significantly 
lower baseline HAMD and BDI scores, but not MADRS 
scores, compared with the nonresponder group. It is possible 
that, in our sample of depressive participants, psychosomatic 
symptoms were more prominent in the nonresponder group, 
which would have resulted in score differences between the 
HAMD and BDI, although there were no differences in the 
MADRS scores, which are related to the mood and cognition/
energy of patients with depression. The cut-off criteria for the 
scales could explain differences in the severity of MDD. In 
this sample, the baseline scores of HAMD were indicative of 
more severe depression. In comparison, the baseline scores 
of MADRS and BDI indicated moderate depression. Putting 
all three assessments together, we felt the intensity was better 
described as moderate, rather than severe, in this sample. 
Because of the known differences in clinician-rated scales 
and self-reported measures,57 for the purpose of this study, the 
results of the three clinical scales were set in the correlation 
with changes in NAA/Cr levels. 
A limitation of this study is that the participants had 
never been treated for depression or other mental illnesses, 
and were not diagnosed with comorbidity; which would 
hardly resemble everyday clinical practice. The number of 
participants in both the responder and nonresponder groups 
was too small for  far-reaching conclusions, so there is a 
need for larger samples. Further limitations include the lack 
of a healthy control group and the inclusion of a placebo for 
further comparative and interpretative purposes. 
In conclusion, this study did not find a significant change 
in the level of NAA/Cr after treatment with antidepressant 
medication, suggesting a prompt beneficial effect of anti-
depressant medication on neuronal integrity or restoration 
in patients experiencing their first episode of MDD. The 
baseline and endpoint NAA/Cr ratios were not significantly 
different between the responder and nonresponder groups, 
and could not serve as biological markers for predicting the 
response to treatment. Additionally, the correlation between 
NAA/Cr and changes in severity of MDD was not significant, 
meaning that the possible role of NAA as a biological cor-
relate of the intensity of MDD and the clinical course could 
not be confirmed.
Considering the fact that antidepressants have an impact 
on both the clinical state and the neurochemistry of the brain, 
it would be expected that some biological changes in brain 
metabolites would follow clinical changes during treatment. 
Further studies are needed to determine conclusively whether 
patients with MDD have a deficit of brain metabolites, and 
how changes in brain metabolites correlate with symptoms, 
onset, outcome, and treatment response. It would also be 
important to determine whether the brain metabolite deficit 
could be reversible after antidepressant treatment, and how 
it could be significant for predicting the individual outcomes 
of treatment and the course of illness. 
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